Hepatology International最新文献

{"title":"Defining the evaluation standards for the cholangiocytic component in cHCC-CCA: a pathology-based perspective.","authors":"Xiaojun Liu, Hao Wang","doi":"10.1007/s12072-025-10923-2","DOIUrl":"https://doi.org/10.1007/s12072-025-10923-2","url":null,"abstract":"","PeriodicalId":12901,"journal":{"name":"Hepatology International","volume":" ","pages":""},"PeriodicalIF":6.1,"publicationDate":"2025-10-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145280090","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Metabolic implications of tenofovir alafenamide in chronic hepatitis B: a commentary on cardiovascular and lipid risks.","authors":"Wenxin Gao, Lingling Xie","doi":"10.1007/s12072-025-10931-2","DOIUrl":"https://doi.org/10.1007/s12072-025-10931-2","url":null,"abstract":"","PeriodicalId":12901,"journal":{"name":"Hepatology International","volume":" ","pages":""},"PeriodicalIF":6.1,"publicationDate":"2025-10-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145274651","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Critical appraisal of diagnostic criteria and statistical methodology in FALD study.","authors":"Lili Yi","doi":"10.1007/s12072-025-10920-5","DOIUrl":"https://doi.org/10.1007/s12072-025-10920-5","url":null,"abstract":"","PeriodicalId":12901,"journal":{"name":"Hepatology International","volume":" ","pages":""},"PeriodicalIF":6.1,"publicationDate":"2025-10-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145225372","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"B-cell subset heterogeneity in the liver during chronic hepatitis B.","authors":"Abdus Salam, Ulrich Kalinke, Matthias Bruhn","doi":"10.1007/s12072-025-10930-3","DOIUrl":"https://doi.org/10.1007/s12072-025-10930-3","url":null,"abstract":"","PeriodicalId":12901,"journal":{"name":"Hepatology International","volume":" ","pages":""},"PeriodicalIF":6.1,"publicationDate":"2025-10-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145212546","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Methodological considerations for interpreting the efficacy of adjuvant therapy in HBV-related HCC.","authors":"Peng Li, Yating Liu, Wei Wang","doi":"10.1007/s12072-025-10927-y","DOIUrl":"https://doi.org/10.1007/s12072-025-10927-y","url":null,"abstract":"","PeriodicalId":12901,"journal":{"name":"Hepatology International","volume":" ","pages":""},"PeriodicalIF":6.1,"publicationDate":"2025-10-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145212493","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Immunomodulation by bepirovirsen may induce killing of infected hepatocytes (B-Together study).","authors":"Shilpy Joshi, Johannes M Freudenberg, Jennifer M Singh, William T Jordan, Leigh Felton, Susan Dixon, Melanie Paff, Dickens Theodore, Jill Walker","doi":"10.1007/s12072-025-10917-0","DOIUrl":"https://doi.org/10.1007/s12072-025-10917-0","url":null,"abstract":"<p><strong>Background: </strong>Bepirovirsen is an investigational drug; its multimodal mechanism of action (MoA) is under evaluation. Observations in treated participants show transient alanine aminotransferase (ALT) increases, alongside hepatitis B surface antigen (HBsAg) declines. We investigated bepirovirsen's MoA in relation to virological response, hepatocyte death, and ALT increases.</p><p><strong>Methods: </strong>In B-Together (NCT04676724), 108 participants on stable nucleos(t)ide analogs received bepirovirsen for 24 (Arm 1) or 12 (Arm 2) Weeks, then up to 24 Weeks of pegylated interferon-α-2a. This post hoc peripheral longitudinal biomarker exploratory analysis examined serum proteomics and whole blood transcriptomics from peripheral blood mononuclear cell samples from 82 participants. Relative expressions of immune- and disease-related biomarkers were measured, and differential expression determined across arms and response subgroups.</p><p><strong>Results: </strong>Increases from baseline in mean expression of serum proteins with immune effector and apoptotic functions (Week 3) and transcripts associated with immune cell proliferation and activation (Week 5) were observed regardless of arm or response subgroup. By Week 8, serum liver and apoptosis-specific proteins were increased; this was more pronounced in responders than non-responders, with the difference more marked in Arm 1 versus Arm 2. Increased abundance of these proteins was highly correlated with ALT levels, which were often associated with transient hepatitis B virus (HBV) DNA elevations and HBsAg decreases.</p><p><strong>Conclusions: </strong>These findings provide evidence that bepirovirsen may modulate the immune system to facilitate infected hepatocyte killing in chronic HBV infection in addition to its direct antiviral effects; therefore, ALT increases could reflect a therapeutic response to bepirovirsen.</p><p><strong>Clinical trial number: </strong>NCT04676724 and NCT04449029.</p>","PeriodicalId":12901,"journal":{"name":"Hepatology International","volume":" ","pages":""},"PeriodicalIF":6.1,"publicationDate":"2025-10-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145212477","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comment on \"Stage‑specific impact of portal hypertension on outcomes after liver resection in hepatocellular carcinoma\".","authors":"Hongmiao Xia, Yu Zhou","doi":"10.1007/s12072-025-10926-z","DOIUrl":"https://doi.org/10.1007/s12072-025-10926-z","url":null,"abstract":"","PeriodicalId":12901,"journal":{"name":"Hepatology International","volume":" ","pages":""},"PeriodicalIF":6.1,"publicationDate":"2025-10-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145212472","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Novel and simplified model for the precise identification of concurrent bacterial infections in patients aged 60 years and older with acute-on-chronic liver diseases: a nationwide, multicentre, prospective cohort study.","authors":"Ju Zou, Hai Li, Guohong Deng, Xianbo Wang, Xin Zheng, Jinjun Chen, Zhongji Meng, Yubao Zheng, Yanhang Gao, Zhiping Qian, Feng Liu, Xiaobo Lu, Yu Shi, Jia Shang, Yan Huang, Ruochan Chen","doi":"10.1007/s12072-025-10855-x","DOIUrl":"10.1007/s12072-025-10855-x","url":null,"abstract":"<p><strong>Objective: </strong>We aimed to develop an effective model to identify the risk of concurrent bacterial infections in older patients with acute-on-chronic liver disease (AoCLD).</p><p><strong>Methods: </strong>Data from 809 individuals aged 60-80 sourced from the CATCH-LIFE cohort were analyzed. Participants were randomly assigned to training and internal validation groups at a ratio of 7:3. An independent cohort of 336 older inpatients with AoCLD from Xiangya Hospital, Central South University was used to conduct an external validation of the model. Independent risk factors were identified using LASSO and logistic regression analysis in the training cohort and were subsequently used to develop a user-friendly model. Model performance was evaluated using area under the curve (AUC), calibration plots, and decision curve analysis in the internal and external validation cohorts. Two different cutoff values were determined to stratify infection risk in older patients with AoCLD.</p><p><strong>Results: </strong>The infection rate among older patients with AoCLD was 30.28%. Pulmonary infections were predominant, accounting for 93% of all infections. Gram-negative bacteria were the most frequently isolated pathogens, representing 64% of cases in this population. The novel model developed to identify bacterial infections included three variables: cirrhosis, absolute neutrophil count, and C-reactive protein (CRP) level. The AUC for the training, internal, and external validation datasets demonstrated high accuracy in identifying bacterial infections (AUC of the training dataset = 0.805, AUC of the internal validation dataset = 0.848, and AUC of the external validation dataset = 0.838). The model significantly outperformed neutrophil count, CRP level, and procalcitonin level alone in detecting bacterial infections among older patients with AoCLD. To facilitate clinical decision-making, we defined two cutoff values of prediction probability: a low cutoff of 32.2% to rule out bacterial infections and a high cutoff of 47.9% to confidently confirm bacterial infections.</p><p><strong>Conclusion: </strong>Our model aids in the early and precise diagnosis of bacterial infections in older patients with AoCLD, thereby facilitating prompt interventions to prevent adverse outcomes.</p>","PeriodicalId":12901,"journal":{"name":"Hepatology International","volume":" ","pages":"1133-1150"},"PeriodicalIF":6.1,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144729901","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Metabolic dysfunction-associated steatotic liver disease increases the incidence of metachronous liver metastases from TNM stage 0-II colorectal cancer.","authors":"Xiangjun Qian, Guojie Long, Qian Wang, Kai Zhang, Yanna Liu, Lei Zhang, Jiancong Xie, Zheyu Zheng, Jinxue Zhou, Dawei Zhang, Chao Ma, Hao Zhuang, Xiaopei Hao, Xiaoming Huang, Weidong Pan","doi":"10.1007/s12072-025-10870-y","DOIUrl":"10.1007/s12072-025-10870-y","url":null,"abstract":"<p><strong>Background and aims: </strong>Metachronous colorectal liver metastases (CRLM) had been the main cause of death in most colorectal cancer (CRC) patients after curative surgery. However, the clinical impact of the pre-existing metabolic dysfunction-associated steatotic liver disease (MASLD) on metachronous CRLM remains unclear, the present study aims to clarify this issue.</p><p><strong>Methods: </strong>This study retrospectively enrolled in 2155 CRC patients who underwent curative surgery at the Sixth Affiliated Hospital of Sun Yat-sen University from 2017 to 2018, including 300 cases with MASLD and 1855 cases of Control group. Cox regression and Kaplan-Meier curves were constructed to evaluate the influencing factors and cumulative incidence of recurrence (CIR) of metachronous CRLM.</p><p><strong>Results: </strong>The pre-existing MASLD was an independent risk factor for metachronous CRLM in TNM stage 0-II CRC patients (HR, 2.696; 95% CI 1.553-4.681; p < 0.001), and this association persisted for both early (HR, 2.309; 95% CI 1.008-5.291; p = 0.048) and late (HR, 2.791; 95% CI 1.321-5.894; p = 0.007) metachronous CRLM. However, pre-existing MASLD was not independently associated with metachronous CRLM in TNM stage III CRC patients. In TNM stage 0-II CRC patients, the 5-year hepatic CIR rate in the MASLD group was significantly higher than that in the Control group (9.3% vs. 4.0%, p < 0.001). MASLD had no significant impact on metachronous extrahepatic metastases for TNM stage 0-II and stage III CRC patients.</p><p><strong>Conclusions: </strong>The pre-existing MASLD is an independent and important risk factor predicting hepatic recurrence for CRC patients of TNM stage 0-II after curative surgery.</p>","PeriodicalId":12901,"journal":{"name":"Hepatology International","volume":" ","pages":"1098-1108"},"PeriodicalIF":6.1,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144798949","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association between depression and metabolic dysfunction-associated steatotic liver disease: a cross-sectional analysis from the paracelsus 10,000 Study.","authors":"Florian Koutny, Vanessa Frey, Christian Datz, Sophie Gensluckner, Julian Prosenz, Patrick Langthaler, Andreas Maieron, Maria Flamm, Daniel Weghuber, Bernhard Iglseder, Eugen Trinka, Bernhard Paulweber, Elmar Aigner, Bernhard Wernly","doi":"10.1007/s12072-025-10922-3","DOIUrl":"https://doi.org/10.1007/s12072-025-10922-3","url":null,"abstract":"<p><strong>Background and aims: </strong>Depression is linked to obesity and metabolic syndrome, but its independent association with metabolic dysfunction-associated steatotic liver disease (MASLD) remains unclear. We examined the association between depressive symptoms and MASLD, independent of other risk factors.</p><p><strong>Methods: </strong>We analyzed cross-sectional data from 7433 participants of the Paracelsus 10,000 study. Depression (BDI-II > 13) and MASLD (FLI ≥ 60 plus ≥ 1 cardiometabolic risk factor) were assessed. Associations were examined using Poisson and linear regression models adjusted for demographics, lifestyle factors, metabolic syndrome, and antidepressant use. Subgroup and interaction analyses explored effect modification.</p><p><strong>Results: </strong>MASLD was more prevalent in participants with depressive symptoms than those without (37% vs. 27%, p < 0.01). Depressive symptoms were independently associated with MASLD (adjusted incidence rate ratio: 1.25, 95% CI: 1.13-1.39, p < 0.01), with consistent findings using continuous BDI-II scores. The association remained robust across subgroups defined by age, metabolic syndrome, education, smoking status, and antidepressant use. No significant differences were observed in fibrosis markers (APRI and FIB-4).</p><p><strong>Conclusion: </strong>In this large, population-based cross-sectional study, depressive symptoms were found to be associated with MASLD, independent of metabolic risk factors and antidepressant use. However, given the observational design and limited detail on antidepressant type, dose, indication, and adherence, the findings should be interpreted with caution and do not support causal conclusions. Nevertheless, findings suggest that mental health considerations may be relevant in MASLD screening and prevention strategies. Further research is needed to explore whether and how antidepressant therapy may relate to liver health.</p>","PeriodicalId":12901,"journal":{"name":"Hepatology International","volume":" ","pages":""},"PeriodicalIF":6.1,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145199155","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}